These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 11797073)

  • 41. Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study.
    Rodgers J; Buchanan T; Scholey AB; Heffernan TM; Ling J; Parrott AC
    J Psychopharmacol; 2003 Dec; 17(4):389-96. PubMed ID: 14870950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users.
    Milani RM; Parrott AC; Turner JJ; Fox HC
    Addict Behav; 2004 Jul; 29(5):965-71. PubMed ID: 15219343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Self-reports of executive dysfunction in current ecstasy/polydrug Users.
    Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
    Cogn Behav Neurol; 2012 Sep; 25(3):128-38. PubMed ID: 22960437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users.
    Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W
    Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
    Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?
    Gouzoulis-Mayfrank E; Becker S; Pelz S; Tuchtenhagen F; Daumann J
    Biol Psychiatry; 2002 May; 51(9):766-9. PubMed ID: 11983191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users.
    Dafters RI; Hoshi R; Talbot AC
    Psychopharmacology (Berl); 2004 May; 173(3-4):405-10. PubMed ID: 12955295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence for significant polydrug use among ecstasy-using college students.
    Wish ED; Fitzelle DB; O'Grady KE; Hsu MH; Arria AM
    J Am Coll Health; 2006; 55(2):99-104. PubMed ID: 17017306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users.
    Parrott AC
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1466-84. PubMed ID: 23660456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive performance amongst recreational users of "ecstasy".
    Rodgers J
    Psychopharmacology (Berl); 2000 Jul; 151(1):19-24. PubMed ID: 10958112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.
    Parrott AC; Lasky J
    Psychopharmacology (Berl); 1998 Oct; 139(3):261-8. PubMed ID: 9784083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study.
    Schilt T; de Win MM; Koeter M; Jager G; Korf DJ; van den Brink W; Schmand B
    Arch Gen Psychiatry; 2007 Jun; 64(6):728-36. PubMed ID: 17548754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.
    Buchert R; Thomasius R; Wilke F; Petersen K; Nebeling B; Obrocki J; Schulze O; Schmidt U; Clausen M
    Am J Psychiatry; 2004 Jul; 161(7):1181-9. PubMed ID: 15229049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.
    de Win MM; Reneman L; Reitsma JB; den Heeten GJ; Booij J; van den Brink W
    Psychopharmacology (Berl); 2004 May; 173(3-4):376-82. PubMed ID: 14726997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.
    Halpern JH; Sherwood AR; Hudson JI; Gruber S; Kozin D; Pope HG
    Addiction; 2011 Apr; 106(4):777-86. PubMed ID: 21205042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Electrophysiological indices of response inhibition in human polydrug users.
    Roberts CA; Fairclough S; Fisk JE; Tames FT; Montgomery C
    J Psychopharmacol; 2013 Sep; 27(9):779-89. PubMed ID: 23803689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cortical oxygenation suggests increased effort during cognitive inhibition in ecstasy polydrug users.
    Roberts CA; Montgomery C
    J Psychopharmacol; 2015 Nov; 29(11):1170-81. PubMed ID: 26333432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
    Gouzoulis-Mayfrank E; Daumann J
    J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.